March 14, 2019
Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
Anticipated 2019 Events include Enrollment in the Planned SPR994
Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206
Phase 1 Clinical Trials in 2H19
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Spero Therapeutics, …